HP&M Honors: Jeff Gibbs Receives FDLI Distinguished Service and Leadership Award; U.S. News Ranks HP&M as a Top FDA Law Firm; Attorneys Contribute to New Book on Health Care Commercialization

It’s been quite a month for Hyman, Phelps & McNamara, P.C. (“HP&M”)!  First, the American Bar Association named the FDA Law Blog to the 2013 ABA Journal Blawg 100 (see here).  Now there are three more honors to report! 

Earlier this week at the Food and Drug Law Institute’s (“FDLI”) Annual Holiday and Leadership Awards Reception, HP&M Director Jeffrey N. Gibbs was honored when the organization awarded him with the 2013 Distinguished Service and Leadership Award.  The award is given each year to as many as four individuals from various areas of the food and drug law community for their notable service and leadership.  Joining Mr. Gibbs in the 2013 award are Jane A. Axelrad, the Associate Director for Policy in FDA’s Center for Drug Evaluation and Research; Kay Holcombe, Vice President of Government Relations and Senior Health Policy Advisor at Genzyme; and Richard Kingham, a partner at Covington & Burling LLP.  (For more on the award recipients, see here).  Mr. Gibbs joins a distinguished list of past award recipients, including HP&M’s Paul M. Hyman (2003) and Stephen H. McNamara (2004).

Moving on . . . .  HP&M has once again been ranked as a “Tier 1” law firm in the area of “FDA Law” (both nationally and in Washington, D.C.) by the folks over at U.S. News & World Report, who  teamed up with Best Lawyers for the “America’s Best Law Firms 2014” rankings.  More than 11,000 law firms are ranked in 120 practice areas in 170 metropolitan areas and 8 states.  “[R]ankings are based on a rigorous evaluation process that includes the collection of client and lawyer evaluations, peer review from leading attorneys in their field, and review of additional information provided by law firms as part of the formal submission process,” according to U.S. News.  The 2014 list of America’s Best Law Firms can be searched here, or viewed here (we’re noted on page 51).

Finally, HP&M has been busy on the publication front.  A new book published by Thomson Reuters, titled “Commercialisation of Health Care: Jurisdictional Comparisons,” delves into how health care products, including drugs, medical devices, biologics, and dietary supplements, are regulated across 21 major jurisdictions throughout the world.  The new book, for which HP&M’s Jeff Gibbs is one of the general editors, includes contributions from expert regulatory lawyers in each jurisdiction.  The chapter on United States regulation was co-authored by HP&M’s Jennifer D. Newberger, Alexander J. Varond, and Jeff Gibbs.